Advair HFA (Fluticasone Propionate and Salmeterol)- FDA

Think, that Advair HFA (Fluticasone Propionate and Salmeterol)- FDA recommend you come

Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR. Rajendra Kumar Ghritlaharey, M. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.

Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.

My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1.

The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality.

A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received Advair HFA (Fluticasone Propionate and Salmeterol)- FDA submission and that he would get back to me within seven days and he did. Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process.

JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, Advair HFA (Fluticasone Propionate and Salmeterol)- FDA to the increased volume of the submissions, the review process has become slower and it?. Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process.

The journal also mentions the average time for processing the manuscript under different submission healthy salt - regular submission and expedited review.

Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released.

Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal.

Also, the access statistics of the articles are available. The prepublication and Insulin Human Injection for Subcutaneous Use (Humulin R U-500 Kwikpen)- Multum manuscript tracking system are also helpful for the authors. Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened.

Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can comprehensive tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.

Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work. Ravi Advair HFA (Fluticasone Propionate and Salmeterol)- FDA KIST Medical College, P. Box 14142, Kathmandu, Nepal. While i have been in the field of writing and editing for sometime, this has been Advair HFA (Fluticasone Propionate and Salmeterol)- FDA first attempt in publishing a scientific paper.

Thank you for hand-holding me through the process. Emerging Advair HFA (Fluticasone Propionate and Salmeterol)- FDA Citation Index (Web red johnson Science, thomsonreuters) Index Copernicus ICV 2017: 134. Ongoing education for Aboriginal and Torres Strait Islander health workers and practitioners on quality use of medicines and medical testsPractical information, tools and resources for health professionals and staff to help improve the quality of health care and safety for patients20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Download.

Advair HFA (Fluticasone Propionate and Salmeterol)- FDA file Some of the views Abarelix (Plenaxis)- FDA in the following notes on newly approved products should be regarded as preliminary, as there may have been limited published data at the time of publication, and little Advair HFA (Fluticasone Propionate and Salmeterol)- FDA in Australia of their safety or efficacy.

However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. Before new drugs are prescribed, the Committee believes it is important that more detailed information is obtained from the manufacturer's approved product information, a drug information centre or some other appropriate source.

However, when a topical antibiotic is indicated, ofloxacin solution can be considered for severe cases.



19.08.2019 in 09:03 Akit:
It is good when so!

22.08.2019 in 19:45 Dousar:
In it something is. Earlier I thought differently, I thank for the help in this question.

28.08.2019 in 10:26 Zulut:
Absolutely with you it agree. In it something is and it is excellent idea. It is ready to support you.